COMMENTARY

Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics

July 26, 2017
By Takashi Ebisawa A third-party probe into a scandal surrounding Xarelto (rivaroxaban) patient surveys wrapped up earlier this month, laying bare a series of problems inside Osaka-based Bayer Yakuhin, the Japan pharma unit Bayer AG. For one, there was a…

To read the full story

COMMENTARY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…